Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:1401:57-72.
doi: 10.1007/5584_2022_719.

Adult Stem Cell Therapy as Regenerative Medicine for End-Stage Liver Disease

Caecilia H C Sukowati  1   2 , Claudio Tiribelli  3
Affiliations

Adult Stem Cell Therapy as Regenerative Medicine for End-Stage Liver Disease

Caecilia H C Sukowati et al. Adv Exp Med Biol. 2022.

Abstract

The increased incidence of end-stage liver disease (ESLD) causes a major burden on the global health system and population health. Liver transplantation (LT) is one of the most effective treatments for ESLD patients, but its practice is extensively hampered by the scarcity of liver donors, the limited number of transplantation centers, the complexity of the procedure, and postoperative complication. In parallel, vast growing advances in cellular biology and biotechnology have opened new alternatives in clinics, including the transplantation of adult stem cells for chronic diseases such as ESLD. Numerous types of stem cells, such as mesenchymal stem cells, hematopoietic stem cells, endothelial progenitor cells, and other cells, obtained from bone marrow, umbilical cord, adipose tissue, or peripheral blood had been isolated and given to ESLD patients all over the world. Many clinical data had demonstrated promising results, indicating its potential. However, conclusive protocol and agreement on adult stem cell definition and transplantation method are still lacking, and thus further research must still be conducted.

Keywords: Adult stem cells; Cell transplantation; End-stage liver disease; Regenerative medicine.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Amer M-EM, El-Sayed SZ, El-Kheir WA, Gabr H, Gomaa AA, El-Noomani N, Hegazy M (2011) Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. Eur J Gastroenterol Hepatol 23(10):936–941. https://doi.org/10.1097/MEG.0b013e3283488b00 - DOI - PubMed
    1. Amin MA, Sabry D, Rashed LA, Aref WM, el-Ghobary MA, Farhan MS, Fouad HA, Youssef YA-A (2013) Short-term evaluation of autologous transplantation of bone marrow-derived mesenchymal stem cells in patients with cirrhosis: Egyptian study. Clin Transpl 27(4):607–612. https://doi.org/10.1111/ctr.12179 - DOI
    1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302):964–967. https://doi.org/10.1126/science.275.5302.964 - DOI - PubMed
    1. Asrani SK, Devarbhavi H, Eaton J, Kamath PS (2019) Burden of liver diseases in the world. J Hepatol 70(1):151–171. https://doi.org/10.1016/j.jhep.2018.09.014 - DOI - PubMed
    1. Au KP, Chan ACY (2019) Is living donor liver transplantation justified in high model for end-stage liver disease candidates (35+)? Curr Opin Organ Transplant 24(5):637–643. https://doi.org/10.1097/MOT.0000000000000689 - DOI - PubMed

LinkOut - more resources